NCT02616497View on ClinicalTrials.gov

ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)

PHASE4CompletedINTERVENTIONAL
Enrollment

1,220

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

February 28, 2017

Study Completion Date

March 28, 2018

Conditions
Atherothrombosis
Interventions
DRUG

Aspirin

COX-1 inhibitor

DRUG

Triflusal

COX-1 inhibitor

Trial Locations (1)

45110

Atherothrombosis Research Centre / Laboratory of Biochemistry, University of Ioannina, Ioannina

All Listed Sponsors
lead

University of Ioannina

OTHER

NCT02616497 - ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS) | Biotech Hunter | Biotech Hunter